Scarica l'app Stockscreener
2.08
4.15%
-0.09
Pre-mercato:
2.10
0.02
+0.96%
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics (NASDAQ: ACRV) sets 2026 virtual meeting, director and auditor votes - Stock Titan
Acrivon Therapeutics shares slide sharply following mixed oncology trial update - MSN
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RA Capital boosts Acrivon (ACRV) stake to 28.8% after ATM share buy - Stock Titan
RA Capital funds add 3,888,888 Acrivon (ACRV) shares at $1.80 - Stock Titan
Acrivon (ACRV) Chief Legal Officer has 558 shares withheld for RSU taxes - Stock Titan
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities - Sahm
Cancer drug pairing drove complete tumor regression in Acrivon lab study - Stock Titan
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
New Acrivon employee gets stock options for 111,150 shares - Stock Titan
Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2%Still a Buy? - MarketBeat
Portfolio Update: What is Acrivon Therapeutics Incs 5 year growth outlookStop Loss & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Market Catalysts: Will Acrivon Therapeutics Inc benefit from rate cuts2026 Drop Watch & Daily Stock Momentum Reports - baoquankhu1.vn
VIX Spike: Is Acrivon Therapeutics Inc gaining market shareWeekly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-04-07 20:07:09 - baoquankhu1.vn
Portfolio Shifts: Can Acrivon Therapeutics Inc expand into new markets2026 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Intraday: Is Acrivon Therapeutics Inc a good ESG investmentQuarterly Profit Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Can Acrivon (ACRV) Stock Go Higher | Price at $1.61, Up 5.92%Overvalued Stocks - Newser
ACRV Stock Price, Quote & Chart | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
AI Stocks: Can Acrivon Therapeutics Inc ride the EV wave2026 Earnings Impact & Community Trade Idea Sharing Platform - baoquankhu1.vn
We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Sahm
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress - Investing.com Australia
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress By Investing.com - Investing.com South Africa
[SCHEDULE 13D/A] Acrivon Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Research Analysts Set Expectations for ACRV Q1 Earnings - marketbeat.com
If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV) - Stock Titan
ACRV Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: What is Acrivon Therapeutics Incs 5 year growth outlook2026 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Form 4 Acrivon Therapeutics Inc For: 4 March By Investing.com - Investing.com Australia
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates - MarketBeat
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus - Investing.com UK
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus By Investing.com - Investing.com Canada
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Acrivon Highlights Positive ACR-368 Data and 2025 Results - TipRanks
ACRV: 52% response rate in serous endometrial cancer and robust cash reserves support ongoing growth - TradingView
BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million - tradingview.com
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Acrivon Therapeutics (ACRV) posts 2025 results, 52% ACR-368 response and $118.6M cash - Stock Titan
Cancer drug study posts 52% response as Acrivon adds new arm - Stock Titan
Acrivon Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $77.9M Net Loss - TradingView
ACRV: Net loss narrowed to $77.9M in 2025; cash runway extends into Q2 2027 - TradingView
Oncology pipeline and AP3 proteomics strategy at Acrivon (NASDAQ: ACRV) - Stock Titan
ACRV Q4'25 Earnings: revenue estimate is 166.29K USD - tradingview.com
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday - MarketBeat
Acrivon Therapeutics, Inc. (ACRV) upgraded to buy: Here's why - MSN
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - The Manila Times
Acrivon Therapeutics to Present Pre-Clinical Data on ACR-368 and ACR-2316 Synergy with ADCs and Immune Checkpoint Inhibitors at 2026 AACR Annual Meeting - geneonline.com
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at - GlobeNewswire
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):